Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulators.

L Schrieber1

  • 1Sydney University Department of Rheumatology, Royal North Shore Hospital, St. Leonards, NSW, Australia.

Agents and Actions. Supplements
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Biologically based immunomodulators, including cytokines and monoclonal antibodies, offer a promising new frontier for treating rheumatic diseases like rheumatoid arthritis. While challenges like allergic reactions exist, this approach represents an exciting advancement in immune-based therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More bark than bite: Comparative studies are needed to determine the importance of canine zoonoses in Aboriginal communities. A critical review of published research.

Zoonoses and public health·2017
Same author

Transmission of Streptococcus dysgalactiae subsp. equisimilis between child and dog in an Aboriginal Australian community.

Zoonoses and public health·2013
Same author

Treatment of Raynaud phenomenon in systemic sclerosis.

Internal medicine journal·2013
Same author

The 2010 Royal Australasian College of Physicians' policy statement 'Circumcision of infant males' is not evidence based.

Internal medicine journal·2012
Same author

Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function.

Internal medicine journal·2008
Same author

'Grape-sultana' sign represents a favourable response to aggressive treatment of early diffuse systemic scleroderma.

Internal medicine journal·2005
Same journal

Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

Agents and actions. Supplements·1998
Same journal

Immunomodulation of Crohn's disease by interleukin-10.

Agents and actions. Supplements·1998
Same journal

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

Agents and actions. Supplements·1998
Same journal

Symposium new drugs for inflammatory, allergic and immunologic disease.

Agents and actions. Supplements·1998
Same journal

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

Agents and actions. Supplements·1998
Same journal

A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

Agents and actions. Supplements·1998
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Biotechnology

Background:

  • Rheumatic diseases involve complex immune system dysregulation.
  • Current treatments may have limitations, necessitating novel therapeutic strategies.
  • Biologically based immunomodulators are emerging as a new class of treatments.

Purpose of the Study:

  • To explore the potential of biologically based immunomodulators in treating rheumatic diseases.
  • To review the applications of cytokines and monoclonal antibodies in immune-based therapies.
  • To discuss the promise and challenges of immunomodulation in rheumatology.

Main Methods:

  • Review of current literature on immunomodulators in rheumatic diseases.
  • Discussion of cytokines (interleukins, interferons) and their therapeutic applications.

Related Experiment Videos

  • Analysis of monoclonal antibody (mca) applications against lymphocyte targets and autoantibodies.

    • Main Results:

    • Cytokines like gamma-interferon show promise in conditions such as rheumatoid arthritis (RA).
    • Monoclonal antibodies have demonstrated success in various immune-related conditions and animal models.
    • Genetic engineering enables synthesis of these complex biological agents.

    Conclusions:

    • Immunomodulation represents an exciting, albeit nascent, therapeutic approach for rheumatic diseases.
    • Potential challenges include allergic reactions to mouse proteins and antibody resistance.
    • Further research and development are crucial for realizing the full potential of these therapies.